For the year ending 2025-12-31, GANX has $22,818,975 in assets. $4,254,227 in debts. $20,837,628 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 20,837,628 | |||
| Tax credits | 179,701 | |||
| Prepaid expenses and other current assets | 1,219,809 | |||
| Total current assets | 22,237,138 | |||
| Property and equipment, net | 74,916 | |||
| Internal-use software, net | 102,837 | |||
| Operating lease right-of-use assets | 334,090 | |||
| Restricted cash | 36,296 | |||
| Long-term deposits and other noncurrent assets | 33,698 | |||
| Total noncurrent assets | 581,837 | |||
| Total assets | 22,818,975 | |||
| Accounts payable | 825,027 | |||
| Operating lease liabilities - current | 119,876 | |||
| Other current liabilities | 2,306,624 | |||
| Loans - current | 100,869 | |||
| Total current liabilities | 3,352,396 | |||
| Defined benefit pension plan | 390,509 | |||
| Operating lease liabilities - noncurrent | 211,238 | |||
| Loans - noncurrent | 300,084 | |||
| Total noncurrent liabilities | 901,831 | |||
| Total liabilities | 4,254,227 | |||
| Common stock, 0.0001 par value 100,000,000 shares authorized 42,073,807 and 27,132,588 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 4,209 | |||
| Additional paid-in capital | 119,139,677 | |||
| Accumulated other comprehensive income (loss) | 776,869 | |||
| Accumulated deficit | -81,194,908 | |||
| Loss of the period | -20,161,099 | |||
| Total stockholders' equity | 18,564,748 | |||
| Total liabilities and stockholders' equity | 22,818,975 | |||
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)